<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR40">
 <label>40.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Thomas</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Sadjadian</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Kollmeier</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Lowe</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Mattson</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Trout</surname>
    <given-names>JR</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer</article-title>
  <source>Investig New Drugs</source>
  <year>2017</year>
  <volume>35</volume>
  <fpage>345</fpage>
  <lpage>358</lpage>
  <pub-id pub-id-type="doi">10.1007/s10637-017-0450-3</pub-id>
  <pub-id pub-id-type="pmid">28303530</pub-id>
 </element-citation>
</ref>
